Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.
Press releases published on June 2, 2025
Bitmine Immersion Technologies, Inc. Announces Uplist to NYSE American Stock Exchange
GlobeNewswire
·
June 2, 2025
LAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) -- Bitmine Immersion Technologies, Inc. (OTCQX: BMNRD) (“Bitmine” or “Company”), a technology company focused on Bitcoin mining using immersion technology, today announced that it expects its shares of common stock …
Stratus Therapeutics Strengthens Executive Team with Appointment of Michael P. Cooke, PhD as Chief Scientific Officer
GlobeNewswire
·
June 2, 2025
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Stratus Therapeutics, Inc. (“Stratus”), a biotechnology company developing on-demand hematopoietic stem cell (HSC) therapies, today announced the appointment of Michael (Mike) P. Cooke, PhD, as Chief …
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting
GlobeNewswire
·
June 2, 2025
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic …
Applied Digital Announces 250MW AI Data Center Lease With CoreWeave in North Dakota
GlobeNewswire
·
June 2, 2025
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD), a designer, builder and operator of next-generation digital infrastructure for HPC applications, has entered into two approximately 15-year lease agreements with …
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
GlobeNewswire
·
June 2, 2025
45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or …
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
GlobeNewswire
·
June 2, 2025
Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstruction Supports broad range of regenerative medicine applications beyond ophthalmology FLORHAM PARK, …
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
·
June 2, 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the …
FDA Accepts TransCon® CNP NDA for Priority Review
GlobeNewswire
·
June 2, 2025
– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared to placebo, with a safety and tolerability profile similar to …
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
June 2, 2025
Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is the most rapidly increasing HNSCC in the US VERSATILE-003 …
CareCloud to Present on AI Innovation at Maxim Group’s 2025 Virtual Tech Conference on June 3, 2025
GlobeNewswire
·
June 2, 2025
Somerset, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in AI-driven healthcare technology solutions for medical practices and health systems nationwide, announced today that its Co- …
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
GlobeNewswire
·
June 2, 2025
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a …
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
GlobeNewswire
·
June 2, 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will …
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
GlobeNewswire
·
June 2, 2025
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol INB-200 is well-tolerated, showing no serious …
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
GlobeNewswire
·
June 2, 2025
WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. …
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
GlobeNewswire
·
June 2, 2025
Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC) Median Overall Survival of 17.3 months in Phase 2 study patients treated with Phase 3 formulation ( …
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 2, 2025
CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule …
Zefiro Publishes Whitepaper for its Lifecycle Solution Suite of Environmental Technologies
GlobeNewswire
·
June 2, 2025
The Zefiro Lifecycle Solution (ZLS) leverages artificial intelligence for advanced modelling and analytics of well selection, leak profiling, environmental attributes, and abatement techniques. It offers an easy-to-use dashboard showing methane leak …
Digi Power X Maintains Strong Cash and Crypto Position With No Long-Term Debt and Reports May 2025 Production Results
GlobeNewswire
·
June 2, 2025
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, June 02, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“ …
New Wave Appoints New Chief Executive Officer
GlobeNewswire
·
June 2, 2025
Vancouver, BC, June 02, 2025 (GLOBE NEWSWIRE) -- New Wave Holdings Corp. (“New Wave” or the “Company”) (CSE:NWAI, FWB:0XM0, OTCPK:TRMNF) announces that Mr. Joshua Matettore has been appointed as Chief Executive Officer (“CEO”) of the Company effective …
Sanborn Achieves SOC 2 Type 2 Attestation, Reinforcing Commitment to Data Security and Operational Integrity
GlobeNewswire
·
June 2, 2025
COLORADO SPRINGS, Colo., June 02, 2025 (GLOBE NEWSWIRE) -- The Sanborn Map Company, Inc. (Sanborn), a leader in geospatial solutions and data services, is proud to announce that it has successfully completed a SOC 2 Type 2 audit. This independent …